Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 19, 2025

APC anti-human CD69

RRID:AB_314844
Type: Antibody

Proper Citation

(BioLegend Cat# 310909, RRID:AB_314844)

Antibody Information

URL: http://antibodyregistry.org/AB_314844

Proper Citation: (BioLegend Cat# 310909, RRID:AB_314844)

Target Antigen: CD69

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD69

Description: This monoclonal targets CD69

Target Organism: human

Clone ID: Clone FN50

Antibody ID: AB_314844

Vendor: BioLegend

Catalog Number: 310909

Alternative Catalog Numbers: 310910

Record Creation Time: 20231110T044956+0000

Record Last Update: 20241115T123817+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD69.

No alerts have been found for APC anti-human CD69.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Li G, et al. (2025) Microenvironmental ?-TrCP negates amino acid transport to trigger CD8+ T cell exhaustion in human non-small cell lung cancer. Cell reports, 44(1), 115128.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Zhao Y, et al. (2023) cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity. Immunity.

Xiao C, et al. (2022) SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response. iScience, 25(3), 103934.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 185(3), 493.

Bibby JA, et al. (2022) Systematic single-cell pathway analysis to characterize early T cell activation. Cell reports, 41(8), 111697.

Luengo A, et al. (2021) Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Molecular cell, 81(4), 691.

Krämer B, et al. (2021) Early IFN-? signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.

Wang Y, et al. (2021) NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell reports, 36(6), 109516.

Xiao C, et al. (2021) Optimization of antigen-specific CD8+ T cell activation conditions for infectious diseases including COVID-19. STAR protocols, 2(3), 100789.

Beatson RE, et al. (2021) TGF-?1 potentiates V?9V?2 T cell adoptive immunotherapy of cancer. Cell reports. Medicine, 2(12), 100473.

Felce SL, et al. (2020) RNA-Seq analysis of early transcriptional responses to activation in the leukaemic Jurkat E6.1 T cell line. Wellcome open research, 5, 42.

van Galen P, et al. (2019) Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell, 176(6), 1265.